Circio Holding ASA (CRNA) - tidl: Targovax (TRVX) 1

[solskimm]

Guider på avtale ja…
Er det noen biotechs som pleier å gjøre denslags?
En ting er “hopes and dreams” en annen ting er å faktisk få det til, attpåtil på en måte som skaper aksjonærverdier - noe EW aldri har klart.

[strongbuy]

Bækkelaget som har en del å lempe ut nå + atlas da… hengemyra vedvarer til 0.-

[TekBot]

Atlas Holdings for CIRCIO

Pursuant to Securities Trading Regulation (STR), section 4-1, Atlas Special Opportunities, LLC hereby notifies you that we have crossed the notification requirement threshold in Circio Holding, with ticker CRNA, NO0013033795. Please see below for details on the ownership details resulting from transactions occurring on October 11, 2024.

Value Date 10/11/2024
…

Vis børsmeldingen

Start of Day Position 1,668,400.00
End of Day Position 1,172,319.00
Outstanding Shares 24,519,674.00
Ownership Percentage 4.7811%

Kilde

[TheObserver]

Her ligger det vel penger på gaten

Artikkel på DN i dag om børsens billigste selskaper.

[Martins]

Hehe, morsomt at i hvert fall Petronor P/E er feil, regner med mye feil i listen.

[bowie]

Aksjen er ned 75% siden emisjonen i sommer…, katastrofe
Atlas er snart tomme, midlertidig
Dette kan snart gi rekyl , men så er det nye trekk på Atlas da … hvor lite kan selskapet være verdt, svaret er jo ett stort 0, men vi er jo ikke her for 0, men at EDW gjengen kan klare noe fra små midler sannsynligheten kan jeg ikke spå dessverre

[VBR]

What are the challenges and advancements driving CGT drug development?

[Den.nye.vinen]

Thomas Hansen on stage i morgen på presisjefylte European Society of Cell and Gene Therapy (ESGCT) 2024, in Rome, Italy. Dette blir spennende!

· ESGCT is one of the most prestigious and widely attended international
conferences in the gene therapy field
  · In the presentation, Circio wil showcase the latest developments and in vivo
data for its circVec circular RNA expression platform designed to enhance gene
therapy

[TekBot]

Circio Holding ASA: Requested Conversion of Convertible Bonds

Reference is made to Circio Holding ASA’s (the “Company”) outstanding
convertible bonds as issued to Atlas Special Opportunities, LLC (“Atlas”) under
the Investment Agreement entered into between Atlas and the Company in March
…

Vis børsmeldingen

Atlas has, by a notice of conversion, requested conversion of convertible bonds
with a nominal value of NOK 500,000 which, pursuant to the bond terms, are
convertible into 833,333 new shares in the Company at a conversion price of NOK
0.6.

The Company’s share capital will accordingly be increased by NOK 499,999.80 by
the issuance of 833,333 new shares upon completion of the conversion by
registration of the share capital increase in the Norwegian Register of Business
Enterprises (Nw.: Foretaksregisteret). Following the conversion, the Company’s
total share capital will be NOK 15,211,804.20 divided into 25,353,007 shares,
each with a nominal value of NOK 0.60.

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@circio.com (erik.wiklund@targovax.com)

Lubor Gaal, CFO
Phone: +34 683343811
Email: lubor.gaal@circio.com (erik.wiklund@targovax.com)

About Circio

Building next generation RNA therapeutics

Circio Holding ASA is a biotechnology company developing novel circular RNA and
immunotherapy medicines.

Circio has established a unique circular RNA (circRNA) platform for genetic
medicine. The proprietary circVec technology is based on a modular genetic
cassette design for efficient biogenesis of multifunctional circRNA from DNA and
viral vectors, which can be deployed in multiple disease settings. The circVec
platform has demonstrated enhanced and more durable protein expression than
classic mRNA vector systems, and has the potential to become the new gold
-standard for DNA and virus-based therapeutics in the future. The circRNA R&D
activities are being conducted by the wholly owned subsidiary Circio AB based at
the Karolinska Institute in Stockholm, Sweden.

In addition, Circio is continuing to develop its legacy oncology program, TG01,
targeting KRAS driver mutations. TG01 is currently being tested in clinical
trials which are being run through academic collaborative networks, supported by
prestigious research grants from Innovation Norway and the Norwegian Research
Council.

Kilde

[Profit]

Har Atlas mistet trua? Ser ut som de bare pøser ut med aksjer selv på en dag hvor Thomas skal gi en presentasjon på ESGCT annual meeting?

[VBR]

Atlas er mest sannsynlig tom for aksjer, så dette tipper jeg er noen andre. Syntes det er litt rart at Circio ikke går ut å melder om dagens presentasjon. De har jo bare embargo inntil 0800AM CEST

[Tippe]

hvor lang tid tar det for dem å få konverter bonds om til aksjer?

[VBR]

Tror det har variert litt tidligere, men trodde det fort gikk 2 - 5 dager?

[Aagaard1]

Hvornår kommer der nyt fra præsentationen?

[VBR]

Har etterspurt hvorfor de ikke bruker muligheten til å reklamere litt, så skal legge ut om jeg får svar

[TekBot]

Circio presents circVec circular RNA in vivo expression proof-of-concept data at ESGCT 2024 annual meeting

· Circio selected to present its circVec circular RNA expression platform at the
European Society of Cell and Gene Therapy (ESGCT) annual meeting in Rome 22-25
October; a prestigious and widely attended international gene therapy conference
…

Vis børsmeldingen

· Circio presented new circVec protein expression data showing statistically
significant advantage vs. conventional mRNA-based vector expression both in
vitro and in vivo
· The circVec 2.1 generation shows 15x increase in protein expression in vivo,
and has the potential to substantially improve on the performance of current
gold-standard gene therapy approaches

Oslo, Norway 24 October 2024 - Circio Holding ASA (OSE: CRNA), a biotechnology
company developing next generation circular RNA vector technology for gene
therapy, today announces the publication of new, strong and statistically
significant circVec circular RNA in vivo expression proof-of-concept data,
presented both in the form of a poster and oral presentation by CTO, Dr. Thomas
B Hansen, at the European Society of Cell and Gene Therapy (ESGCT) annual
meeting 2024.

“Circio continues to build momentum with the unique and powerful circVec
platform. We selected the prestigious ESGCT meeting to present our latest
results as it provided a great opportunity to showcase our technology to a broad
life science industry and academic audience,” said Dr. Thomas B. Hansen, CTO of
Circio. “circVec significantly outperforms mRNA-based expression both in vitro
and in vivo and has the potential to offer substantial enhancement over current
gold-standard gene therapy approaches.”

In the ESGCT presentation, Circio showed the evolution and improvements of the
circVec platform from the initial circVec 1.0 design to the current generation
2.1. Long-term in vivo experiments have now demonstrated that circVec 2.1
robustly outperforms classical mRNA-based expression over time, offering
enhanced durability that reaches up to 15-fold higher reporter signals in mouse
models. Additionally, a machine-learning approach to codon optimization has
generated a novel circVec 2.2 design, delivering a further 2-4-fold increase in
protein yield.

Circio is currently testing the performance of circVec 2.1 and 2.2 in both viral
and DNA vector systems in multiple tissues and disease settings in vivo. These
data will guide future development and partnering strategy for the circVec
platform.

The ESGCT slides and poster are attached hereto, and will also be made available
on www.circio.com

Title of presentation and poster:

Optimization of in vitro and in vivo performance of circVec, a vector-based
circular RNA expression platform for enhanced gene therapy

Presenter: Dr. Thomas B Hansen, CTO

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@circio.com

Neil Hunter, Hunter PR
Phone: +44 7821 255568
Email: neiljameshunter@gmail.com

About Circio

Building next generation RNA therapeutics
Circio Holding ASA is a biotechnology company developing novel circular RNA gene
therapies and immunotherapy medicines.

Circio has established a unique circular RNA (circRNA) expression platform for
genetic medicine. The proprietary circVec technology is based on a modular
genetic cassette design for efficient biogenesis of multifunctional circRNA from
DNA and viral vectors, which can be deployed in multiple disease settings,
including cell and gene -therapy and chronic diseases. The circVec platform has
demonstrated enhanced and more durable protein expression vs. classic mRNA
vector systems and has the potential to become the new gold-standard for DNA and
virus-based therapeutics in the future. The circRNA R&D activities are being
conducted by the wholly owned subsidiary Circio AB based at the Karolinska
Institute in Stockholm, Sweden.

In addition, Circio is developing a pan-RAS cancer vaccine, TG01, targeting KRAS
driver mutations. TG01 is currently being tested in two clinical trials: RAS
-mutated pancreatic and lung cancer in the USA and multiple myeloma in Norway.
These studies are being run through academic and industry collaborative
networks, supported by prestigious research grants from Innovation Norway and
the Norwegian Research Council, creating read-outs and future optionality for
the program at low cost to Circio.

Kilde

[Tippe]

får i det minste håpe Atlas blir kvitt alle aksjene de konverterte sist…

[Do2Do]

@anon79663630

Status Atlas pr i dag (etter mine beregninger)

Fin oversikt, har du ajourført denne siste tiden?

[Durable]

40% opp og tre nye innlegg på tråden i dag.

Tidene har forandret seg i norsk biotek.

[VBR]

Vi er vel ikke så mange igjen her? Ruben har forresten tatt forum pause (ref regneark over)